Reagent for research, diagnostic tool. BORIS protein has been identified as Cancer-Testis Antigen (CTA) with testis-specific paralogue of the CCCTC-binding factor. Recent studies have demonstrated that d BORIS is directly responsible for the transcriptional activation of TSP50 (testes-specific protease 50).
| Inventor | Institute |
|---|---|
| Elena Klenova | University of Essex |
| Cat. #: | 152812 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Cancer types: | Genitourinary cancer |
| Research Fields: | Cancer;Genetics |
| Application: | ChIP ; ELISA ; IHC ; IF ; IP ; WB |
| Target: | BORIS |
| Reactivity: | Human |
| Clone: | 20B11 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | Brother of the regulator of imprinted sites, Cancer/testis antigen 27, CCCTC binding factor (zinc finger protein) like, CCCTC-binding factor, CT27, CTCF paralog, CTCF T, CTCF-like protein, Ctcfl, CTCFL_HUMAN, dJ579F2.2, HMG 1L1, HMGB1L1, MGC163358, MGC16915, MGC16916 |
|---|---|
| Product description: | Reagent for research, diagnostic tool. BORIS protein has been identified as Cancer-Testis Antigen (CTA) with testis-specific paralogue of the CCCTC-binding factor. Recent studies have demonstrated that d BORIS is directly responsible for the transcriptional activation of TSP50 (testes-specific protease 50). |
| Conjugation: | Unconjugated |
| Isotype: | IgG3 kappa |
| Molecular weight: | 83 kDa |
| Immunogen: | Synthetic peptide within the BORIS C-terminal domain (aa 614-648) (CG)GEMFPVACRETTARVKEE (NB – the first two aa do not belong to BORIS) |
| Target background: | BORIS protein has been identified as Cancer-Testis Antigen (CTA) with testis-specific paralogue of the CCCTC-binding factor. Recent studies have demonstrated that d BORIS is directly responsible for the transcriptional activation of TSP50 (testes-specific protease 50). |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Debruyne et al. 2019. Nature. 572(7771):676-680. PMID: 31391581. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.